Cas No.: | 77327-05-0 |
Chemical Name: | Didemnin B (9CI) |
SMILES: | COC1=CC=C(C=C1)C[C@@H]2N(C)C(=O)[C@H]3N(CCC3)C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@H](O)[C@@H]([C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@H]4N(CCC4)C(=O)[C@H](C)O)[C@@H](C)OC2=O |
Formula: | C57H89N7O15 |
M.Wt: | 1112.35446 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Didemnin B is a depsipeptide extracted from the marine tunicate Trididemnin cyanophorum. Didemnin B can be used for the research of cancer[1]. |
In Vivo: | Didemnin B is a potent inhibitor of L1210 growth[1]. |
In Vitro: | Didemnin B has activity against miirine B16 melanoma, P388 leukemia, and M5076 sarcoma[1]. |
References: | [1]. Stewart JA, et al. A phase I clinical trial of didemnin B. Cancer. 1991;68(12):2550-2554 |